Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia - 1 Jul 2023

Arvanitakis Alexandros, Holme Pål Andre, Berntorp Erik, Astermark Jan

Abstract excerpt

INTRODUCTION: The timing of prophylaxis and F8 genotype can impact treatment outcomes in adults with severe haemophilia A (HA). AIM: To investigate how F8 genotype, timing, and type of prophylaxis influence arthropathy, bleeding rates, factor consumption and health-related quality of life (HRQoL). METHODS: Thirty-eight patients with severe HA were enrolled. Bleeding events were recorded retrospectively during...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Factor VIII
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemophilia A

Share to Hemorrhage

Share to Joint Diseases

Share to Quality of Life

Source

Identifiers

PMID: 37252898
DOI: 10.1111/hae.14806

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A.PMID 37252898Read ↗

The bleeding phenotype in people with nonsevere hemophilia.Semantic proximity Read ↗

Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A.Semantic proximity Read ↗

Factor VIII/factor IX prophylaxis for severe hemophilia.Semantic proximity Read ↗

Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A.Semantic proximity Read ↗

Prophylaxis for severe hemophilia: experience from Europe and the United States.Semantic proximity Read ↗

Bleeding phenotype according to factor level in 825 children with nonsevere hemophilia: data from the PedNet cohort.Semantic proximity Read ↗

Clinical severity of haemophilia A: does the classification of the 1950s still stand?Semantic proximity Read ↗

Clinical phenotype of severe and moderate haemophilia: Who should receive prophylaxis and what is the target trough level?Semantic proximity Read ↗

Delphi Consensus Recommendations for the Definition of a Severe Bleeding Phenotype and Initiation of Prophylaxis in Patients With Non-Severe Haemophilia.Semantic proximity Read ↗

Patients with moderate hemophilia A and B with a severe bleeding phenotype have an increased burden of disease.Semantic proximity Read ↗

Analysis of single-center Hemophilia A patients :demographics, clinical characteristics and treatment strategiesSemantic proximity Read ↗

Individualizing primary prophylaxis in patients with hemophilia A and B, adherence and new products.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.